AbbVie (ABBV) has received approval from Health Canada for Skyrizi, or risankizumab, in patients aged six to under 18 with moderate to severe plaque psoriasis who qualify for syst ...

Tuesday that Health Canada has approved SKYRIZI (risankizumab) to treat children with moderate to severe plaque psoriasis. The treatment will be gi ...

AbbVie (NYSE: ABBV), announced today that Health Canada has approved SKYRIZI® (risankizumab) for the treatment of pediatric patients aged 6 to <18 years of age with moderate to severe plaque psoriasis ...

Topical celecoxib and garlic-derived diallyl trisulfide gels eased psoriasis-like skin disease and itch in mice by ...

Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...

Angela Fitch, MD, co-founder and chief medical officer of Knownwell and past president of the Obesity Medicine Association, ...

Psoriasis can follow you into the bedroom, turning what should be an enjoyable moment into a worry about what someone might ...

At Fall Clinical 2026, Joel Gelfand, MD, MSCE, reviewed GLP-1 candidacy, weight conversations, and an upcoming monotherapy ...

ORKA-001 ultra-long-acting psoriasis data (PASI 100/90), cash runway, and catalysts. Click for more on ORKA stock.

New Delhi: Psoriasis is often mistaken for a skin condition characterised by red, scaly patches, but its impact extends far ...

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that more than 70% of patients receiving its oral psoriasis ...

A Japanese case report of co-localized psoriasis and vitiligo reveals that IL-23 blockade cleared psoriasis but not vitiligo, ...